Andreas Hochhaus: Asciminib vs. Bosutinib in Chronic Myeloid Leukemia

Andreas Hochhaus, MD, discusses results from a phase I study suggesting asciminib may have superior efficacy to bosutinib in patients with heavily pretreated chronic myeloid leukemia.